Recent Updates
Recently added Catalysts
NKTR Positive Sentiment

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

Monday, December 15, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Nektar Therapeutics will hold a conference call on December 16, 2025, to discuss topline results from the 36-week induction treatment period of its Phase 2b REZOLVE-AA study. The study evaluates rezpegaldesleukin, a Treg proliferator, for treating severe alopecia areata. The results will be shared via a press release and webcast.
Price reaction · baseline $53.3 (2025-12-15 close) · hit after-hours · 1 other NKTR headline(s) in the window, move may be shared
day 0 close
-7.8%
day 1 · peak
-14.8%
day 3
-12.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Nektar is advancing its investigational therapy for alopecia areata.
  • The upcoming conference call will provide important topline results.
  • The company is focused on innovative immunology therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+186%
120-day peak, hindsight
Typical move
10.2%
average across 4 past catalysts
Cash runway
~40 mo
Minimal dilution risk
Lead asset
Rezpegaldesleukin
Phase 3 · Moderate-to-Severe Atopic Dermatitis

Full Press Release Details

SAN FRANCISCO,Dec. 15, 2025/PRNewswire/ -- Nektar Therapeutics (Nasdaq:NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week induction treatment period in the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Tuesday, December 16, 2025 at 8:00 am ET / 5:00 am PT.

Conference Call

The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at thisLINK.
The event, the press release and the slides will also be available on the events section of the Nektar website athttps://ir.nektar.com/events-and-presentations/events. A replay of the webcast will be available for at least 30 days following the event.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Nektar is headquartered in San Francisco, California. For further information, visitwww.nektar.comand follow us onLinkedIn.

For Investors:Vivian Wu628-895-0661

Corey Davis, Ph.D.LifeSci Advisors, LLC[email protected]212-915-2577
Ahu Demir, Ph.D.LifeSci Advisors, LLC[email protected]212-915-3820

For Media:

Frequently Asked Questions

What is the purpose of the Nektar conference call?

The conference call will discuss topline results from the REZOLVE-AA Phase 2b study.

When will the Nektar conference call take place?

The call is scheduled for December 16, 2025, at 8:00 am ET.

What is rezpegaldesleukin used for?

Rezpegaldesleukin is being evaluated for treating severe alopecia areata.

How can I access the Nektar webcast?

The webcast can be accessed via a link provided in the press release.

ShareAdd on Google
Tags: NKTR Viatris Investor Conferences Healthcare Nektar Therapeutics rezpegaldesleukin alopecia areata Phase 2b study clinical trial
Last updated: Dec 15, 2025

Biotech snapshot

Cash runway
$1023M liquidity · $25M/mo burn
~40 mo
Minimal dilution risk
Lead asset
RezpegaldesleukinPhase 3
Moderate-to-Severe Atopic Dermatitis →

Catalyst track record

+186%
best trade around NKTR's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for NKTR.

See every catalyst's timing & PoA →